Draft FDA guidance could be a boon for gene therapy developers
at seekingalpha.com (Tue, 2-Jun 1:50 PM)
BEAM-302 Shows Durable Gene Correction in Alpha-1 Antitrypsin Deficiency—New Data Points to One-Time Therapy Potential
Market Chameleon (Tue, 19-May 11:18 AM)
BEAM-302 Achieves Key Milestone: 94% Corrected Protein and 84% Mutant Reduction Mark Pivotal Progress in AATD Trial
Market Chameleon (Wed, 25-Mar 7:32 AM)
